These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38293023)

  • 41. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram.
    McLeod CJ; Ackerman MJ; Nishimura RA; Tajik AJ; Gersh BJ; Ommen SR
    J Am Coll Cardiol; 2009 Jul; 54(3):229-33. PubMed ID: 19589435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
    Rader F; Oręziak A; Choudhury L; Saberi S; Fermin D; Wheeler MT; Abraham TP; Garcia-Pavia P; Zwas DR; Masri A; Owens A; Hegde SM; Seidler T; Fox S; Balaratnam G; Sehnert AJ; Olivotto I
    JACC Heart Fail; 2024 Jan; 12(1):164-177. PubMed ID: 38176782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center.
    Desai MY; Hajj-Ali A; Rutkowski K; Ospina S; Gaballa A; Emery M; Asher C; Xu B; Thamilarasan M; Popovic ZB
    Prog Cardiovasc Dis; 2024 Feb; ():. PubMed ID: 38354765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prolonged mHealth-Based Arrhythmia Monitoring in Patients With Hypertrophic Cardiomyopathy (HCM-PATCH): Protocol for a Single-Center Cohort Study.
    Schulze Lammers S; Lawrenz T; Lawin D; Hoyer A; Stellbrink C; Albrecht UV
    JMIR Res Protoc; 2023 Dec; 12():e52035. PubMed ID: 38157231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
    Wheeler MT; Olivotto I; Elliott PM; Saberi S; Owens AT; Maurer MS; Masri A; Sehnert AJ; Edelberg JM; Chen YM; Florea V; Malhotra R; Wang A; Oreziak A; Myers J
    JAMA Cardiol; 2023 Mar; 8(3):240-247. PubMed ID: 36652223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and validation of an electrocardiographic artificial intelligence model for detection of peripartum cardiomyopathy.
    Karabayir I; Wilkie G; Celik T; Butler L; Chinthala L; Ivanov A; Moore Simas TA; Davis RL; Akbilgic O
    Am J Obstet Gynecol MFM; 2024 Apr; 6(4):101337. PubMed ID: 38447673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment].
    Lancellotti P; de Marneffe N; Scheen A
    Rev Med Liege; 2024 Feb; 79(2):120-128. PubMed ID: 38356430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toward ECG-based analysis of hypertrophic cardiomyopathy: a novel ECG segmentation method for handling abnormalities.
    Nezamabadi K; Mayfield J; Li P; Greenland GV; Rodriguez S; Simsek B; Mousavi P; Shatkay H; Abraham MR
    J Am Med Inform Assoc; 2022 Oct; 29(11):1879-1889. PubMed ID: 35923089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mavacamten decreases maximal force and Ca
    Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
    Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of electrocardiographic changes and myocardial fibrosis in patients with hypertrophic cardiomyopathy detected by cardiac magnetic resonance imaging.
    Song BG; Yang HS; Hwang HK; Kang GH; Park YH; Chun WJ; Oh JH
    Clin Cardiol; 2013 Jan; 36(1):31-5. PubMed ID: 23070984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy.
    Burstein Waldman C; Owens A
    Future Cardiol; 2021 Oct; 17(7):1269-1275. PubMed ID: 34018809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram.
    Ko WY; Siontis KC; Attia ZI; Carter RE; Kapa S; Ommen SR; Demuth SJ; Ackerman MJ; Gersh BJ; Arruda-Olson AM; Geske JB; Asirvatham SJ; Lopez-Jimenez F; Nishimura RA; Friedman PA; Noseworthy PA
    J Am Coll Cardiol; 2020 Feb; 75(7):722-733. PubMed ID: 32081280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Model for classification of heart failure severity in patients with hypertrophic cardiomyopathy using a deep neural network algorithm with a 12-lead electrocardiogram.
    Togo S; Sugiura Y; Suzuki S; Ohno K; Akita K; Suwa K; Shibata SI; Kimura M; Maekawa Y
    Open Heart; 2023 Dec; 10(2):. PubMed ID: 38056911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy.
    Tian Z; Wang F; Jin W; Zhang Q; Zhou J; Yang P; Wang G; Hsu P; Sun J; Zhang S; Han Y
    BMJ Open; 2023 Jun; 13(6):e071473. PubMed ID: 37336533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Majority of Participants With Suspected Hypertrophic Cardiomyopathy Documented During Screening Echocardiography Have a Normal Electrocardiogram.
    Movahed MR; Irannejad K; Bates S
    Crit Pathw Cardiol; 2024 Mar; 23(1):20-25. PubMed ID: 38381652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Distinct ECG Phenotypes Identified in Hypertrophic Cardiomyopathy Using Machine Learning Associate With Arrhythmic Risk Markers.
    Lyon A; Ariga R; Mincholé A; Mahmod M; Ormondroyd E; Laguna P; de Freitas N; Neubauer S; Watkins H; Rodriguez B
    Front Physiol; 2018; 9():213. PubMed ID: 29593570
    [No Abstract]   [Full Text] [Related]  

  • 58. Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide.
    Willeford A; Silva Enciso J
    Pharmacotherapy; 2023 Dec; 43(12):1397-1404. PubMed ID: 37688422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy.
    Sawan MA; Prabakaran S; D'Souza M; Behbahani-Nejad O; Gold ME; Williams BR; Bilen O
    Clin Cardiol; 2024 Jan; 47(1):e24207. PubMed ID: 38269637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics and Outcomes of Elderly Patients With Hypertrophic Cardiomyopathy.
    Alashi A; Smedira NG; Popovic ZB; Fava A; Thamilarasan M; Kapadia SR; Wierup P; Lever HM; Desai MY
    J Am Heart Assoc; 2021 Feb; 10(3):e018527. PubMed ID: 33506683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.